Halozyme's lead drug flops in PhI­II, forc­ing CEO to ax 160 and re­set fo­cus on tech plat­form

Halozyme’s lead drug has crashed and burned in Phase III, forc­ing CEO He­len Tor­ley to scrap the en­tire pro­gram, trig­ger a com­pa­ny re­struc­tur­ing to slash costs and shift fo­cus to mar­ket­ing its plat­form drug de­liv­ery tech­nol­o­gy.

The da­ta from the Phase III of PEGPH20 in pan­cre­at­ic can­cer were bleak. Their drug $HA­LO com­bined with Abrax­ane ac­tu­al­ly fell short of a con­trol arm dosed with gem­c­itabine and nab-pa­cli­tax­el alone — 11.2 months for their com­bo com­pared to 11.5 months for the con­trol.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA